Biomarker study using exosomes to predict the effect of immune checkpoint inhibitors on primary lung cancer

Biomarker study using exosomes to predict the effect of immune checkpoint inhibitors on primary lung cancer - Biomarker study using exosomes to predict the effect of immune checkpoint inhibitors

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039609

Enrollment

200

Registered

2020-02-26

Start date

2020-02-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Pathologically diagnosed with primary lung cancer 2)Scheduled to start treatment with immune checkpoint inhibitors (with or without concomitant use with cytotoxic chemotherapy) 3)Provided informed consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Biomarker for predicting the effects and the adverse events of immune checkpoint inhibitors	—

Countries

Japan

Contacts

Public ContactKeita Miura

Juntendo University Respiratory Medicine

k-miura@juntendo.ac.jp03-5802-1063

Outcome results